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Abstract Human papillomavirus virus-like particles (VLPs)
have recently been used to deliver genes into mammalian cells
in vitro and in vivo. Here, we investigated whether VLPs may
serve as an e⁄cient carrier of low molecular weight compounds
(e.g. hormones, vitamins, peptides etc.) into cells. COS7 cells
were incubated with recombinant HPV-16L1/L2 VLPs labelled
with the £uorescence dye carboxy£uorescein diacetate succini-
midyl ester. Using £ow cytometry, we demonstrate that labelled
VLPs can speci¢cally bind to the cell surface followed by their
complete internalisation. Our results indicate that VLPs are
promising vehicles for highly e⁄cient delivery of low molecular
weight compounds into cells.
. 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Human papillomaviruses (HPV) are small, non-enveloped
DNA viruses comprising a large group with more than 100
subtypes described so far. HPV exclusively infect basal cells of
epithelia in skin and mucosa in vivo, causing mild pathogenic
lesions such as benign genital warts and more severe diseases
like pre-malignant cervical/penile intraepithelial neoplasia
and/or invasive carcinoma (reviewed in [1]).
HPV capsids show a T=7 eicosahedral symmetry about 55
nm in diameter containing a single molecule of circular dou-
ble-stranded DNA of approximately 8000 bp in length [2].
Each virion contains 360 molecules of the major capsid pro-
tein L1 forming 72 pentamers, the so-called capsomers [3]. In
addition, around 12 molecules of the minor capsid protein L2
are included in the virus shell [4].
Upon synthesis in eukaryotic cells using various expression
systems, L1 and L2 proteins spontaneously self-assemble into
recombinant virus-like particles (VLPs) [5^8]. Comparative
studies of native virions and recombinant VLPs produced in
Escherichia coli [9], yeast [8] and insect cells [5^7] showed that
they are similar with regard to the morphological structure
and cell binding [10,11]. Therefore VLPs represent a useful
model system to study di¡erent aspects of the HPV infection
cycle, in particular their cell binding and uptake. It has re-
cently been shown that VLPs bind to the cell surface via
heparan sulphate followed by their internalisation [12,13].
Earlier, VLPs were used to generate pseudovirions contain-
ing non-HPV DNA molecules. Pseudovirion studies demon-
strated that di¡erent genes of interest can be transferred in
vitro in a wide range of cell types by HPV VLPs leading to the
production of heterologous proteins [14^17].
In order to elucidate whether VLPs can be used as a general
carrier vehicle to transport low molecular weight cargo into
target cells in vitro, we chose carboxy£uorescein diacetate
succinimidyl ester (CFDA-SE) as a model substrate. After
labelling of HPV-16L1/L2 VLPs with CFDA-SE, COS7 cells
were incubated with these VLPs. Our results demonstrated
that HPV-16L1/L2 VLPs represent a useful carrier system to
deliver low molecular weight molecules into mammalian cells.
2. Materials and methods
2.1. Cell culture conditions
All cell culture media and supplements were obtained from Invitro-
gen (Karlsruhe, Germany). COS7 cells were cultured as adherent
monolayer in Dulbecco’s modi¢ed Eagle’s medium (DMEM) supple-
mented with 10% foetal calf serum, 1 mM sodium pyruvate at 37‡C
under 5% CO2 atmosphere.
2.2. Antibodies
The following antibodies were used: (i) mouse monoclonal anti-
body (mAb; clone 33L1-7) recognising linear epitope aa 303^313
(ESQLFNKPYWL) of HPV-33 capsid protein L1 [18], (ii) goat
anti-mouse IgG horseradish peroxidase-conjugated antiserum (Sigma,
Taufkirchen, Germany), (iii) polyclonal rabbit antiserum K75 raised
against recombinant HPV-16L1 protein containing neutralising anti-
bodies and (iv) mAb (clone 16L1-56E) raised against HPV-16L1 VLPs
recognising the native capsid conformation.
2.3. Production and puri¢cation of HPV-16L1/L2 VLPs
VLPs were generated in Sf9 insect cells by co-infection with re-
combinant baculoviruses carrying the L1 and L2 gene of HPV-16
kindly provided by J.T. Schiller and puri¢ed according to Volpers
et al. [7].
2.4. CFDA-SE labelling of HPV-16L1/L2 VLPs
Puri¢ed HPV-16L1/L2 VLPs were diluted in phosphate-bu¡ered
saline (PBS, pH 8.5) to 0.5 mg/ml, and then CFDA-SE (Molecular
Probes, Eugene, OR, USA) was added to a ¢nal concentration of 10
WM or 100 WM. VLPs were omitted from control reactions. After
incubation for 1 h at room temperature in the dark, reactions were
subjected to centrifugation in a sucrose density gradient containing
30% (w/w) and 70% (w/v) steps (2 h at 42 000 rpm in a SW60 rotor) to
separate VLPs from free CFDA-SE. Under these conditions CFDA-
SE remains on the top of the gradient as visualised by £uorescent
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CFSE, which is formed due to spontaneous decay in aqueous solu-
tions. 200 Wl fractions were collected from the bottom, aliquots of
each fraction were subjected to 12.5% SDS^PAGE and analysed by
Western blot ECL detection using primary mAb 33L1-7 (1:500) and
horseradish peroxidase-conjugated goat anti-mouse secondary antise-
rum (1:5000). The integrity of VLP conformation was tested by en-
zyme-linked immunosorbent assays (ELISA) using heparin-coated
and uncoated microtitre plates in combination with mAbs 16L1-56E
and 33L1-7 as described by Giroglou et al. [13].
2.5. Cellular uptake assay
The assay was performed according to Unckell et al. [15] with our
modi¢cations. Brie£y, 1^2 Wg of labelled VLPs in PBS (pH 6.8, 0.1
mg/ml bovine serum albumin, BSA) was incubated with 1.5U105
COS7 cells either as a monolayer or as a suspension culture for 1 h
at 4‡C. In the case of monolayer culture, the supernatant containing
VLPs was removed; cells were washed twice with PBS followed by
incubation at 37‡C in DMEM for the indicated periods of time. COS7
cells grown as suspension cultures were treated with VLPs for 1 h at
4‡C, then directly transferred into 6-well plates and incubated in
DMEM at 37‡C for the indicated periods of time.
2.6. Flow cytometric analysis
COS7 cells infected by CFSE-labelled VLPs were washed and re-
suspended in FACS bu¡er (2% foetal calf serum in PBS, pH 7.2).
Measurements were performed using FACSCalibur (excitation laser
frequency was 488 nm) and CELLQuest software (Becton Dickinson,
Heidelberg, Germany). Typically, 20 000 events were collected. Re-
cordings were made at green £uorescence (FL1) and data were ex-
pressed as histograms.
2.7. Fluorescence microscopy
COS7 cells grown on glass coverslips were incubated with CFSE-
labelled VLPs and CFDA-SE for 1 h at 4‡C followed by 18 h at 37‡C.
Cells were washed with PBS and ¢xed with isopropanol for 30 min.
They were examined with a Zeiss 510 laser scan microscope.
3. Results
3.1. Generation and puri¢cation of CFSE-labelled HPV-16L1/
L2 VLPs
To test whether HPV-16L1/L2 VLPs can e¡ectively deliver
low molecular weight compounds into mammalian cells, we
used CFDA-SE as a £uorescent marker to label VLPs recom-
binantly produced in Sf9 cells. After puri¢cation of HPV-
16L1/L2 VLPs by two subsequent centrifugations in cesium
chloride density gradient [7], the fractions were tested using
Western blot analysis to con¢rm the co-assembly of L1 and
L2 proteins in VLPs. We demonstrated that both capsid pro-
teins co-migrated at a density of 1.29 g/cm3 suggesting that L1
and L2 were incorporated into VLPs (data not shown). Two
di¡erent CFDA-SE concentration (10 and 100 WM) were used
to label puri¢ed HPV-16L1/L2 VLPs resulting in a covalent
amide bond between £uorescence dye and lysine residues of
L1 and L2 proteins [19]. The reactive £uorochrome is gener-
ated by conversion of carboxy£uorescein diacetate to anionic
carboxy£uorescein through intracellular esterases after the en-
try into cells [19]. Control reactions in the absence of VLPs
were performed in addition. To obtain highly puri¢ed £uores-
cent VLPs, non-bound CFDA-SE was separated from labelled
VLPs by centrifugation in a sucrose step gradient followed by
12.5% SDS^PAGE. Under the conditions chosen CFDA-SE
does not migrate into the gradient whereas Western blot anal-
ysis revealed that fractions 5 and 6 from the 30^70% sucrose
interface contained a strong 55 kDa band corresponding to
L1 protein of VLPs (Fig. 1). Results shown in Figs. 2^5 dem-
onstrate that these VLPs indeed contain the label. The two
peak fractions were pooled and used in all subsequent experi-
ments. In addition, the corresponding fractions from the con-
trol gradients loaded with CFDA-SE alone were also pooled.
Intact conformation of generated labelled VLPs was checked
using a heparin^BSA-based ELISA method [13] with mAb
16L1-56E. This experiment clearly showed that the labelled
VLPs had a similar reactivity with mAb 16L1-56E as unla-
belled ones (data not shown).
Fig. 1. Puri¢cation of CFSE-labelled HPV-16L1/L2 VLPs. Puri¢ed
CFSE-labelled VLPs were subjected to centrifugation in a sucrose
density gradient (30% (w/w) and 70% (w/v) sucrose steps). Aliquots
of displayed fractions were separated by 12.5% SDS^PAGE and an-
alysed by Western blotting using the mAb 33L1-7. C, control
(HPV-16L1 VLPs); T, top fraction.
Fig. 2. Flow cytometric analysis of HPV-16L1/L2 VLP association
with COS7 cells. COS7 cells were incubated with the indicated com-
pounds in suspension and subsequently analysed by £ow cytometry
after 18 h. A: Control (auto£uorescence of COS7 cells). B: Incuba-
tion with 2 Wg unlabelled VLPs. C: Incubation with free CFDA-SE
(100 WM). D: Incubation with 1^2 Wg VLPs labelled with 100 WM
CFDA-SE.
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3.2. VLP-mediated delivery of £uorescence dye CFSE to COS7
cells
To measure the delivery of CFSE-labelled HPV-16L1/L2
VLPs to COS7 cells, we incubated the cells with CFSE-la-
belled VLPs ¢rst for 1 h at 4‡C, then for 18 h at 37‡C fol-
lowed by a £ow cytometric analysis. As a negative control,
COS7 cells were treated in the same manner with unlabelled
VLPs or without them. It was demonstrated that 99% of
COS7 cells being cultured with CFSE-labelled HPV-16L1/L2
VLPs were CFSE-positive (Fig. 2D). In negative control
probes, only 1^2% cells showed background £uorescence
(Fig. 2A,B). These data were reproduced in several indepen-
dent experiments. Results were essentially the same when 10
or 100 WM CFDA-SE was used for labelling. To exclude the
possibility that the determined £uorescence is caused by non-
bound CFDA-SE dye co-migrating with the labelled VLPs in
fractions 5 and 6 of the sucrose gradient during the puri¢ca-
tion procedure (see Fig. 1), COS7 cells were also incubated
with the corresponding fractions from the control gradient. As
shown in Fig. 2C, the number of CFSE-positive cells (2%) is
similar to that in negative controls.
From these results we conclude that HPV-16L1/L2 VLPs
may be a highly e⁄cient transport vehicle delivering low mo-
lecular weight compounds to cells.
3.3. Speci¢c blockage of HPV-16L1/L2 VLP binding to COS7
cells by anti-L1 polyclonal antiserum
To answer the question whether the binding of labelled
VLP to cells is a speci¢c process, we performed an inhibition
study using di¡erent polyclonal antisera. CFSE-labelled HPV-
16L1/L2 VLPs were incubated with the neutralising antiserum
K75 or with pre-immune serum as a negative control followed
by culturing with COS7 cells for 18 h, and £ow cytometric
analysis. Antiserum K75, which was generated in rabbits
against HPV-16L1 VLPs, neutralises HPV-16 pseudoinfection
and blocks VLP interaction with the cell surface (data not
Fig. 3. HPV-16L1/L2 VLP binding is inhibited by VLP-speci¢c anti-
serum. Approximately 250 ng CFSE-labelled HPV-16L1/L2 VLPs
(10 WM CFDA-SE) was pre-incubated for 1 h with the indicated
polyclonal antisera (1:100). Then COS7 cells were incubated with
these VLPs for 18 h and subsequently analysed by £ow cytometry.
A: Control (auto£uorescence of COS7 cells). B: Incubation with
CFSE-labelled VLPs. C: Incubation with CFSE-labelled VLPs pre-
incubated with pre-immune serum. D: Incubation with CFSE-la-
belled VLPs pre-treated with VLP neutralising antiserum K75.
Fig. 4. E¡ect of trypsin treatment on the uptake of CFSE-labelled
VLPs into COS7 cells. COS7 cells were incubated with 1^2 Wg
CFSE-labelled VLPs (10 WM CFDA-SE) in suspension followed by
a £ow cytometric analysis. A: After a 1 h incubation at 4‡C, the
cells were treated as indicated. B: The cells were incubated for 1 h
at 4‡C, then 18 h at 37‡C followed by the treatment as shown. Con-
trols represent the auto£uorescence of COS7 cells.
Fig. 5. Uptake of CFSE-labelled VLPs in vesicular structures. La-
belled VLPs were incubated with COS7 cells for 1 h at 4‡C followed
by 18 h at 37‡C. A: COS7 cells+free CFSE. B: COS7 cells+CFSE-
labelled VLPs. Cells were ¢xed and analysed by confocal microsco-
py using a Zeiss 510 laserscan microscope.
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shown). Fig. 3 shows one representative experiment out of
several independent inhibition tests. Pre-incubation of labelled
VLPs with antiserum K75 strongly decreased the number of
CFSE-positive cells in comparison to untreated labelled VLPs
(from 75 to 13%; mean £uorescence level from 31 to 5%; Fig.
3B,D). In contrast, pre-treatment with the control antiserum
caused only slight reduction of the number of CFSE-positive
cells (Fig. 3B,C).
Taken together, these data underline the speci¢c binding of
labelled VLPs to the cell surface.
3.4. Uptake of CFDA-labelled HPV-16L1/L2 VLPs into COS7
cells
CFDA-SE is stable in aqueous solutions only for a short
time since the diacetate ester bonds of CFDA-SE can be
spontaneously hydrolysed by water and converted into the
active £uorochrome without the action of intracellular ester-
ases. Therefore we could not exclude that a fraction of CFSE-
labelled VLPs is activated before entering the cells. To prove
that CFSE-labelled VLPs are indeed internalised into COS7
cells, protease protection experiments were performed. COS7
cells were incubated for 1 h at 4‡C with labelled VLPs fol-
lowed by removal of unbound VLPs. The cells were then
either directly treated with trypsin or incubated for 18 h at
37‡C followed by protease treatment. As shown in Fig. 4A,
trypsin addition after 1 h incubation at 4‡C resulted in a
reduction of the number of CFSE-positive cells to the back-
ground level (from 69 to 1%). In contrast, after 18 h incuba-
tion the £uorescence label was resistant to trypsin (95 and
97% CFSE-positive cells with and without protease treatment,
respectively; Fig. 4B). These data suggest that the vast major-
ity of VLPs were internalised by the cells and no longer served
as a substrate for the extracellularly added trypsin.
Intracellular localisation of the labelled VLPs was con-
¢rmed by confocal laser microscopy. COS7 cells treated
with CFSE-labelled VLPs and free CFDA-SE dye, respec-
tively, showed that labelled-VLPs are localised in vesicular
structures, whereas free CFDA-SE is homogeneously distrib-
uted in the cell (Fig. 5).
In summary, these data underline the uptake of VLPs by
mammalian cells and their possible use as a carrier vehicle to
introduce low molecular weight compounds into cells.
4. Discussion
In the last 10 years many virus-based gene transfer systems
have been established and used in di¡erent approaches for
DNA vaccination and gene therapy in vitro and in vivo (re-
viewed in [21]). Recently papillomavirus VLPs of di¡erent
genotypes consisting of capsid proteins L1 and L2 [15,17] or
only L1 [18] were packed with non-viral DNA and success-
fully transferred into a wide variety of cell types in vitro and
in vivo. In addition, papillomavirus VLPs consisting of a fu-
sion between the major capsid protein L1 and proteins or
peptides of interest (chimeric VLPs) were applied in prophy-
lactic and therapeutic vaccination studies [20,22]. However,
little is known about the ¢eld of application of papillomavirus
VLPs to transport low molecular weight substances into tar-
get cells in vitro and in vivo. Successful encapsidation of £uo-
rescence dye propidium iodide into polyomavirus VLPs was
recently shown by Goldman et al. [23], but the transfer of
generated £uorescence particles into the cells was not inves-
tigated. Using CFDA-SE as a test molecule, we have now
demonstrated that VLPs can serve as an e⁄cient carrier for
uptake of low molecular weight compounds into cells.
After incubation of COS7 with CFSE-labelled VLPs, we
measured their internalisation by £ow cytometry. Our results
demonstrate (i) a speci¢c binding of labelled VLPs to the cell
surface and (ii) an e⁄cient uptake of £uorescently labelled
particles into COS7 cells. Attachment of HPV-11L1 VLPs,
HPV-16 and -33 pseudovirions to the cell surface was shown
to be mediated by an interaction between the major capsid
protein L1 of the viral particle and heparan sulphate mole-
cules exposed extracellularly [12,13]. It is very likely that the
labelled particles also use proteoglycans for their cell attach-
ment. It is not known so far whether these cell surface mol-
ecules also directly mediate the uptake of VLPs or whether
transfer to a secondary receptor is required.
Using a neutralising polyclonal antiserum, we were able to
inhibit the speci¢c cell binding of labelled VLPs which was
re£ected by a strong decrease of CFSE-positive cells (Fig. 3).
Since our experimental system could not distinguish between
interaction of VLPs with the cell surface and their uptake into
the cells, we performed protease protection experiments. Dur-
ing the 1 h incubation at 4‡C, CFSE-labelled VLPs were
bound extracellularly to their primary receptor and did not
enter the cells because of endocytosis blockage at 4‡C [14]. In
contrast, all £uorescent particles were resistant to trypsin
treatment after incubation for 18 h at 37‡C suggesting an
entry of CFSE-labelled VLPs into target cells.
Therefore, HPV VLPs could be an e⁄cient alternative to
commonly used synthetic polymer- and liposome-based deliv-
ery systems sharing with the latter such properties as (i) a high
transfer rate, (ii) a target speci¢city, and (iii) a protection
against degradation (reviewed in [24]). Importantly, the target
speci¢city of HPV in vivo to epithelial cells of the skin and
mucosa [1] o¡ers the opportunity to use these carriers as an
attractive transepithelial delivery system.
Taken together, the data presented in this report suggest
that HPV VLPs are promising vehicles for delivery of bio-
logically active low molecular weight compounds into mam-
malian cells.
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